EVIO (OTCQB: EVIO) this morning announced that it has signed a non-binding Letter of Intent (“LOI”) to acquire 60% of C3 Labs, LLC. C3 Labs is located in Berkeley, CA, which accelerates the company’s intent to expand into Northern California prior to the anticipated increase in demand for analytical testing services. Subject to customary closing conditions, the transaction is expected to close in the first quarter of 2018. “C3 Labs been serving the cannabis industry for years, providing product formulation, research and development services that aligns with EVIO’s longer term strategy to expand our scope of services. We are working to close this transaction in an expeditious manner to begin serving the California market by first quarter 2018,” EVIO CEO William Waldrop stated in the news release.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More
EVIO, Inc. (EVIO) Signs Non-Binding LOI to Acquire Licensed Cannabis Laboratory in Berkeley, CA
